리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 09월
페이지 정보:영문 179 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 백혈구 제거 요법 시장은 2030년까지 1억 4,370만 달러에 달할 전망
2023년에 8,970만 달러로 추정된 세계의 백혈구 제거 요법 시장은 2030년에는 1억 4,370만 달러에 달하며, 분석 기간인 2023-2030년의 CAGR은 7.0%로 성장할 것으로 예측됩니다. 백혈구 제거 요법 디바이스는 본 리포트에서 분석한 부문의 하나이며, CAGR은 7.1%를 기록하며, 분석 기간 종료시에는 1억 2,260만 달러에 달할 것으로 예측됩니다. 백혈구 제거 요법 일회용·부문의 성장률은 분석 기간 중 CAGR 6.0%로 추정됩니다.
미국 시장은 2,460만 달러, 중국은 CAGR 6.5%로 성장할 것으로 예측
미국의 백혈구 제거 요법 시장은 2023년에 2,460만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 2,220만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년의 CAGR은 6.5%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 6.7%와 5.6%로 예측됩니다. 유럽에서는 독일이 CAGR 5.8%로 성장할 것으로 예측됩니다.
세계의 백혈구 제거 요법 시장 - 주요 동향과 촉진요인 정리
백혈구 제거 요법이란 무엇이며, 왜 치료에서 그 중요성이 커지고 있는가?
백혈구제거요법은 혈액내 백혈구(백혈구)를 선택적으로 제거하는 의료 시술로, 백혈병, 다발성골수종, 자가면역질환 등 다양한 질환의 치료에 활용되고 있습니다. 백혈병, 다발성골수종, 자가면역질환 등 다양한 질환의 치료에 사용되는 경우가 많아지고 있습니다. 이 방법은 치료와 연구 모두에서 중요한 역할을 하므로 그 중요성이 더욱 커지고 있습니다. 치료적 응용에서 백혈구 제거 요법은 일부 암 환자에서 위험한 백혈구 수치 증가를 억제하는 데 사용됩니다. 연구 분야에서는 CAR-T 세포 치료와 같은 새로운 치료법을 개발 및 시험하기 위해 백혈구를 채취하는 데 사용됩니다. 고급 치료 옵션에 대한 수요가 증가함에 따라 백혈구 제거 요법은 의료 분야에서 필수적인 툴이 되고 있습니다.
기술의 발전은 백혈구 제거 요법 시장에 어떤 영향을 미치고 있는가?
기술의 발전은 백혈구 제거 요법 시장의 성장에 중요한 역할을 하고 있습니다. 보다 효율적이고 자동화된 어펠레시스 장비의 개발은 환자에게 더 안전하고, 더 빠르고, 더 편안한 시술을 가능하게 했습니다. 이러한 발전은 또한 CAR-T 세포 치료와 같은 치료의 성공에 특히 중요한 백혈구의 높은 수율을 가능하게 했습니다. 또한 백혈구 제거 요법의 기술 혁신은 합병증 위험을 줄이고 환자 결과를 개선하고 있습니다. 기술이 계속 발전함에 따라 백혈구 제거 요법의 효과와 접근성이 더욱 향상되어 임상과 연구 모두에서 채택될 것으로 기대됩니다.
백혈구 제거 요법이 암 치료의 발전에 어떤 역할을 하는가?
백혈구 제거 요법은 암 치료의 발전, 특히 CAR-T 세포 요법과 같은 면역 요법의 발전에 중요한 역할을 하고 있습니다. 이 치료법은 백혈구 제거 요법을 통해 환자의 혈액에서 T세포를 채취하여 암세포를 표적으로 삼아 파괴하도록 유전자 재조합을 하는 것입니다. 이러한 개별화된 암 치료법은 특히 일부 백혈병 및 림프종 환자에서 유망한 결과를 보여주고 있습니다. 이러한 치료법의 성공이 증가함에 따라 치료 과정에서 중요한 단계인 백혈구 제거 요법에 대한 수요가 증가하고 있습니다. 더 많은 면역 요법이 개발되고 승인됨에 따라 백혈구 제거 요법의 사용이 확대되고 암 치료의 미래에 중요한 요소가 될 것으로 예상됩니다.
백혈구 제거 요법 시장의 성장을 가속하는 요인은 무엇인가?
백혈구 제거 요법 시장의 성장은 암 및 자가면역질환의 유병률 증가, 아펠레시스 기술의 발전, 맞춤형 의료에 대한 수요 증가 등 여러 가지 요인에 기인합니다. 또한 백혈구 제거 요법을 사용하여 면역 세포를 수집하는 면역 요법의 채택이 증가하고 있는 것도 큰 원동력이 되고 있습니다. 또한 새로운 치료법 개발에 초점을 맞춘 임상시험 및 연구 활동의 확대는 백혈구 제거 요법 시술에 대한 수요를 증가시키고 있습니다. 의료계가 새로운 치료법을 모색하고 기존 치료법을 개선하는 가운데, 백혈구 제거 요법 시장은 현대 의학의 발전에 중요한 역할을 하는 만큼 지속적인 성장이 예상됩니다.
조사 대상 기업의 예(총 12건)
Allcells LLC
Asahi Kasei Medical Co., Ltd.
BioIVT
Caltag Medsystems Limited
Fresenius SE & Co. KGaA
Haemonetics Corporation
HemaCare Corporation
Key Biologics, LLC.
MacoPharma SA
Ppa Research Group, Inc.
Precision Medicine Group, Inc.
StemCell Technologies Inc.
StemExpress
Terumo BCT, Inc.
Zenbio, Inc.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장의 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global Leukapheresis Market to Reach US$143.7 Million by 2030
The global market for Leukapheresis estimated at US$89.7 Million in the year 2023, is expected to reach US$143.7 Million by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Leukapheresis Devices, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$122.6 Million by the end of the analysis period. Growth in the Leukapheresis Disposables segment is estimated at 6.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$24.6 Million While China is Forecast to Grow at 6.5% CAGR
The Leukapheresis market in the U.S. is estimated at US$24.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$22.2 Million by the year 2030 trailing a CAGR of 6.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.
Global Leukapheresis Market - Key Trends & Drivers Summarized
What Is Leukapheresis and Why Is It Gaining Importance in Medical Treatments?
Leukapheresis is a medical procedure that involves the selective removal of white blood cells (leukocytes) from the blood, which is increasingly being used in the treatment of various diseases, including leukemia, multiple myeloma, and autoimmune disorders. This procedure is gaining importance due to its critical role in both therapeutic and research settings. In therapeutic applications, leukapheresis is used to reduce high white blood cell counts, which can be dangerous in certain cancer patients. In research, it is employed to collect leukocytes for use in developing and testing new therapies, such as CAR-T cell therapy. As the demand for advanced treatment options grows, leukapheresis is becoming an essential tool in the medical field.
How Are Technological Advancements Impacting the Leukapheresis Market?
Technological advancements are playing a significant role in the growth of the leukapheresis market. The development of more efficient and automated apheresis machines has made the procedure safer, faster, and more comfortable for patients. These advancements are also enabling higher yields of leukocytes, which is particularly important for the success of therapies like CAR-T cell therapy. Additionally, innovations in leukapheresis techniques are reducing the risk of complications and improving patient outcomes. As technology continues to evolve, it is expected to further enhance the efficacy and accessibility of leukapheresis, driving its adoption in both clinical and research settings.
What Role Does Leukapheresis Play in the Advancement of Cancer Therapies?
Leukapheresis is playing a crucial role in the advancement of cancer therapies, particularly in the development of immunotherapies such as CAR-T cell therapy. In this process, leukapheresis is used to collect T cells from the patient’s blood, which are then genetically modified to target and destroy cancer cells. This personalized approach to cancer treatment has shown promising results, especially in patients with certain types of leukemia and lymphoma. The increasing success of these therapies is driving demand for leukapheresis, as it is a critical step in the treatment process. As more immunotherapies are developed and approved, the use of leukapheresis is expected to expand, making it a key component in the future of cancer treatment.
What Factors Are Driving the Growth of the Leukapheresis Market?
The growth in the leukapheresis market is driven by several factors, including the increasing prevalence of cancer and autoimmune diseases, advancements in apheresis technology, and the rising demand for personalized medicine. The growing adoption of immunotherapies, which rely on leukapheresis for the collection of immune cells, is also a significant driver. Additionally, the expansion of clinical trials and research activities focused on developing new treatments is boosting the demand for leukapheresis procedures. As the medical community continues to explore new therapeutic applications and improve existing ones, the leukapheresis market is expected to experience sustained growth, driven by its critical role in advancing modern medical treatments.
Select Competitors (Total 12 Featured) -
Allcells LLC
Asahi Kasei Medical Co., Ltd.
BioIVT
Caltag Medsystems Limited
Fresenius SE & Co. KGaA
Haemonetics Corporation
HemaCare Corporation
Key Biologics, LLC.
MacoPharma SA
Ppa Research Group, Inc.
Precision Medicine Group, Inc.
StemCell Technologies Inc.
StemExpress
Terumo BCT, Inc.
Zenbio, Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Leukapheresis - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advancements in Apheresis Technology Propel Adoption of Leukapheresis in Therapeutic Applications
Shift Towards Personalized Medicine Expands Addressable Market for Leukapheresis
Rising Focus on Cell-Based Therapies and Immunotherapy Drives Adoption in Cancer Treatment
Rising Importance of Leukapheresis in Bone Marrow Transplantation Strengthens Demand
Growing Application of Leukapheresis in Stem Cell Collection Strengthens Market Demand
Technological Innovations in Leukapheresis Devices Enhance Efficiency and Patient Comfort
Expanding Use of Leukapheresis in Hematology and Oncology Generates New Opportunities
Push for High-Purity Cell Collection Fuels Demand in Clinical and Research Settings
Increasing Adoption of Leukapheresis in CAR-T Cell Therapy Accelerates Market Expansion
Technological Advancements in Automated and Continuous Flow Systems Expand Market Potential
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Blood Component Providers & Blood Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Blood Component Providers & Blood Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Blood Component Providers & Blood Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Leukapheresis Market Analysis of Annual Sales in US$ for Years 2014 through 2030
TABLE 14: World Recent Past, Current & Future Analysis for Leukapheresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Leukapheresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Leukapheresis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Disposables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Disposables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Disposables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Hospital & Transfusion Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Hospital & Transfusion Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Hospital & Transfusion Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Leukapheresis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 36: USA Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 37: USA 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
CANADA
TABLE 38: Canada Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 41: Canada Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 43: Canada 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 46: Canada 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
JAPAN
Leukapheresis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 47: Japan Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 49: Japan 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 50: Japan Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 52: Japan 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 55: Japan 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
CHINA
Leukapheresis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 56: China Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 57: China Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 58: China 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 59: China Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 60: China Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 61: China 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 63: China Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 64: China 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
EUROPE
Leukapheresis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 65: Europe Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 66: Europe Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 67: Europe 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 70: Europe 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Leukapheresis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Leukapheresis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 73: Europe 16-Year Perspective for Leukapheresis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
FRANCE
Leukapheresis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 77: France Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 78: France Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 79: France 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 80: France Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 81: France Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 82: France 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 84: France Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 85: France 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
GERMANY
Leukapheresis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 86: Germany Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 87: Germany Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 88: Germany 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 89: Germany Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 91: Germany 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 94: Germany 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
ITALY
TABLE 95: Italy Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 96: Italy Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 97: Italy 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 98: Italy Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 100: Italy 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 103: Italy 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
UNITED KINGDOM
Leukapheresis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 104: UK Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 105: UK Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 106: UK 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 107: UK Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 108: UK Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 109: UK 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 111: UK Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 112: UK 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 114: Rest of Europe Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 115: Rest of Europe 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 117: Rest of Europe Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 118: Rest of Europe 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 120: Rest of Europe Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 121: Rest of Europe 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Leukapheresis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 123: Asia-Pacific Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 124: Asia-Pacific 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 126: Asia-Pacific Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 127: Asia-Pacific 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 129: Asia-Pacific Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 130: Asia-Pacific 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 131: Rest of World Recent Past, Current & Future Analysis for Leukapheresis by Application - Research and Therapeutic - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of World Historic Review for Leukapheresis by Application - Research and Therapeutic Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of World 16-Year Perspective for Leukapheresis by Application - Percentage Breakdown of Value Sales for Research and Therapeutic for the Years 2014, 2024 & 2030
TABLE 134: Rest of World Recent Past, Current & Future Analysis for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of World Historic Review for Leukapheresis by End-Use - Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of World 16-Year Perspective for Leukapheresis by End-Use - Percentage Breakdown of Value Sales for Blood Component Providers & Blood Centers, Academic & Research Institutes, Pharma & Biotech Companies and Hospital & Transfusion Centers for the Years 2014, 2024 & 2030
TABLE 137: Rest of World Recent Past, Current & Future Analysis for Leukapheresis by Offering - Devices and Disposables - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
TABLE 138: Rest of World Historic Review for Leukapheresis by Offering - Devices and Disposables Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
TABLE 139: Rest of World 16-Year Perspective for Leukapheresis by Offering - Percentage Breakdown of Value Sales for Devices and Disposables for the Years 2014, 2024 & 2030